The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker
Authors
Keywords
immunotherapy, cancer therapy, biomarker, mutattional load, genetics
Journal
CANCER CELL
Volume 39, Issue 2, Pages 154-173
Publisher
Elsevier BV
Online
2020-10-30
DOI
10.1016/j.ccell.2020.10.001
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Baseline plasma tumor mutation burden predicts response to pembrolizumab-based therapy in patients with metastatic non-small cell lung cancer
- (2020) Charu Aggarwal et al. CLINICAL CANCER RESEARCH
- Pembrolizumab (P) in patients (Pts) with colorectal cancer (CRC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
- (2020) Eyal Meiri et al. JOURNAL OF CLINICAL ONCOLOGY
- The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers into breast cancer clinical trials and daily practice
- (2020) Paula I Gonzalez‐Ericsson et al. JOURNAL OF PATHOLOGY
- Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer
- (2020) Sohyun Hwang et al. Scientific Reports
- Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity
- (2020) Shumei Kato et al. OncoImmunology
- ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy
- (2020) Ryosuke Okamura et al. Journal for ImmunoTherapy of Cancer
- Pan-cancer analysis of KEAP1 mutations as biomarkers for immunotherapy outcomes
- (2020) Xiaoxia Chen et al. Annals of Translational Medicine
- Small-Cell Carcinoma of the Ovary, Hypercalcemic Type–Genetics, New Treatment Targets, and Current Management Guidelines
- (2020) Marc Tischkowitz et al. CLINICAL CANCER RESEARCH
- MHC-I genotype and tumor mutational burden predict response to immunotherapy
- (2020) Aaron M. Goodman et al. Genome Medicine
- Burden of tumor mutations, neoepitopes, and other variants are weak predictors of cancer immunotherapy response and overall survival
- (2020) Mary A. Wood et al. Genome Medicine
- Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer
- (2020) Naiyer A. Rizvi et al. JAMA Oncology
- High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naïve Patients with Diverse Cancers
- (2020) Paul Riviere et al. MOLECULAR CANCER THERAPEUTICS
- Role of ultraviolet mutational signature versus tumor mutation burden in predicting response to immunotherapy
- (2020) Timothy V. Pham et al. Molecular Oncology
- The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies
- (2020) Shogo Kumagai et al. NATURE IMMUNOLOGY
- Tumor mutational load predicts survival after immunotherapy across multiple cancer types
- (2019) Robert M. Samstein et al. NATURE GENETICS
- Association of Tumor Microenvironment T-Cell Repertoire and Mutational Load With Clinical Outcome After Sequential Checkpoint Blockade in Melanoma
- (2019) Erik Yusko et al. Cancer Immunology Research
- Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non–Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel
- (2019) Zhijie Wang et al. JAMA Oncology
- Initial results from a phase II study of nivolumab (NIVO) plus ipilimumab (IPI) for the treatment of metastatic castration-resistant prostate cancer (mCRPC; CheckMate 650).
- (2019) Padmanee Sharma et al. JOURNAL OF CLINICAL ONCOLOGY
- Genomic biomarkers of response to nivolumab/ipilimumab (nivo/ipi) and nivolumab (nivo) monotherapy in 108 patients with advanced renal cell carcinoma.
- (2019) Chung-Han Lee et al. JOURNAL OF CLINICAL ONCOLOGY
- First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers
- (2019) Neal Ready et al. JOURNAL OF CLINICAL ONCOLOGY
- FDA Approval Summary: Pembrolizumab for the treatment of microsatellite instability-high solid tumors
- (2019) Leigh Marcus et al. CLINICAL CANCER RESEARCH
- Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities
- (2019) Yada Kanjanapan et al. CANCER
- A Compendium of Mutational Signatures of Environmental Agents
- (2019) Jill E. Kucab et al. CELL
- Phenotypic and Genomic Determinants of Immunotherapy Response Associated with Squamousness
- (2019) Aaron M. Goodman et al. Cancer Immunology Research
- Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade
- (2019) Steve Lu et al. JAMA Oncology
- Tumor mutational burden quantification from targeted gene panels: major advancements and challenges
- (2019) Laura Fancello et al. Journal for ImmunoTherapy of Cancer
- Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy
- (2019) Aaron M. Goodman et al. Cancer Immunology Research
- 1192OAssociation of tumour mutational burden with outcomes in patients with select advanced solid tumours treated with pembrolizumab in KEYNOTE-158
- (2019) A Marabelle et al. ANNALS OF ONCOLOGY
- LBA83Final efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC)
- (2019) M Socinski et al. ANNALS OF ONCOLOGY
- LBA80Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: Tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407
- (2019) L Paz-Ares et al. ANNALS OF ONCOLOGY
- Immune cell PD-L1 co-localizes with macrophages and is associated with outcome in PD-1 pathway blockade therapy
- (2019) Yuting Liu et al. CLINICAL CANCER RESEARCH
- Neoantigens and genome instability: impact on immunogenomic phenotypes and immunotherapy response
- (2019) Elaine R. Mardis Genome Medicine
- The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity
- (2019) Chengming Liu et al. CANCER LETTERS
- Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer
- (2018) Matthew D. Hellmann et al. CANCER CELL
- Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer
- (2018) Matthew D. Hellmann et al. CANCER CELL
- Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer
- (2018) Yi-Mi Wu et al. CELL
- Atezolizumab (atezo) vs. chemotherapy (chemo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): Immune biomarkers, tumor mutational burden (TMB), and clinical outcomes from the phase III IMvigor211 study.
- (2018) Thomas Powles et al. JOURNAL OF CLINICAL ONCOLOGY
- Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers
- (2018) Min Yuen Teo et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing
- (2018) Hira Rizvi et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
- (2018) Kohei Shitara et al. LANCET
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
- (2018) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
- (2018) Diana Miao et al. SCIENCE
- MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma
- (2018) Scott J. Rodig et al. Science Translational Medicine
- STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
- (2018) Ferdinandos Skoulidis et al. Cancer Discovery
- Increased diversity with reduced “diversity evenness” of tumor infiltrating T-cells for the successful cancer immunotherapy
- (2018) Akihiro Hosoi et al. Scientific Reports
- Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors
- (2018) Aaron M. Goodman et al. JAMA Oncology
- Evolutionary Pressure against MHC Class II Binding Cancer Mutations
- (2018) Rachel Marty et al. CELL
- Determinants of high tumor mutational burden (TMB) and mutational signatures in breast cancer.
- (2018) Romualdo Barroso-Sousa et al. JOURNAL OF CLINICAL ONCOLOGY
- Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
- (2018) David R. Gandara et al. NATURE MEDICINE
- Successful Treatment of HIV-Associated Kaposi Sarcoma with Immune Checkpoint Blockade
- (2018) Natalie Galanina et al. Cancer Immunology Research
- Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
- (2018) T A Chan et al. ANNALS OF ONCOLOGY
- LBA55Primary efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC)
- (2018) E S Kim et al. ANNALS OF ONCOLOGY
- Cancer Neoantigens
- (2018) Ton N. Schumacher et al. Annual Review of Immunology
- Dynamics of tumor and immune responses during immune checkpoint blockade in non-small cell lung cancer
- (2018) Valsamo Anagnostou et al. CANCER RESEARCH
- T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028
- (2018) Patrick A. Ott et al. JOURNAL OF CLINICAL ONCOLOGY
- Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
- (2018) Razvan Cristescu et al. SCIENCE
- Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma
- (2018) Sabrina A. Hogan et al. Cancer Immunology Research
- Integrated analysis of the immunological and genetic status in and across cancer types: impact of mutational signatures beyond tumor mutational burden
- (2018) Jan Budczies et al. OncoImmunology
- APOBEC-related mutagenesis and neo-peptide hydrophobicity: implications for response to immunotherapy
- (2018) Amélie Boichard et al. OncoImmunology
- Comprehensive Genomic Profiling Reveals Diverse but Actionable Molecular Portfolios across Hematologic Malignancies: Implications for Next Generation Clinical Trials
- (2018) Natalie Galanina et al. Cancers
- Concordance between Comprehensive Cancer Genome Profiling in Plasma and Tumor Specimens
- (2017) Judith N. Müller et al. Journal of Thoracic Oncology
- OA20.01 Tumor Mutation Burden (TMB) is Associated with Improved Efficacy of Atezolizumab in 1L and 2L+ NSCLC Patients
- (2017) Marcin Kowanetz et al. Journal of Thoracic Oncology
- Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
- (2017) Arjun V Balar et al. LANCET
- Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis
- (2017) Samra Turajlic et al. LANCET ONCOLOGY
- Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
- (2017) Aaron M. Goodman et al. MOLECULAR CANCER THERAPEUTICS
- A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy
- (2017) Marta Łuksza et al. NATURE
- Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
- (2017) Ahmet Zehir et al. NATURE MEDICINE
- First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
- (2017) David P. Carbone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- (2017) Joaquim Bellmunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor Mutational Burden and Response Rate to PD-1 Inhibition
- (2017) Mark Yarchoan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
- (2017) Diego Chowell et al. SCIENCE
- Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma
- (2017) Martin Lauss et al. Nature Communications
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
- (2017) Zachary R. Chalmers et al. Genome Medicine
- Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis
- (2017) Alexandra Snyder et al. PLOS MEDICINE
- High expression of PD-1 ligands is associated with kataegis mutational signature and APOBEC3 alterations
- (2017) Amélie Boichard et al. OncoImmunology
- Baseline tumor T cell receptor (TcR) sequencing analysis and neo antigen load is associated with benefit in melanoma patients receiving sequential nivolumab and ipilimumab
- (2016) J. Weber et al. ANNALS OF ONCOLOGY
- Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set
- (2016) Jason Roszik et al. BMC Medicine
- Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
- (2016) Willy Hugo et al. CELL
- Mutational Landscape and Sensitivity to Immune Checkpoint Blockers
- (2016) R. M. Chabanon et al. CLINICAL CANCER RESEARCH
- Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
- (2016) Stéphane Champiat et al. CLINICAL CANCER RESEARCH
- The emerging role of immune checkpoint inhibition in malignant lymphoma
- (2016) Ida Hude et al. HAEMATOLOGICA
- PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
- (2016) Margaretha G.M. Roemer et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
- (2016) Tanguy Y Seiwert et al. LANCET ONCOLOGY
- Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy
- (2016) Nadeem Riaz et al. NATURE GENETICS
- PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
- (2016) Paul T. Nghiem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- The "cancer immunogram"
- (2016) C. U. Blank et al. SCIENCE
- Mutational signatures associated with tobacco smoking in human cancer
- (2016) L. B. Alexandrov et al. SCIENCE
- Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
- (2016) Daniel Sanghoon Shin et al. Cancer Discovery
- The emerging role of immune checkpoint inhibition in malignant lymphoma
- (2016) Ida Hude et al. HAEMATOLOGICA
- Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade
- (2016) D. B. Johnson et al. Cancer Immunology Research
- Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy
- (2016) Sadakatsu Ikeda et al. npj Genomic Medicine
- Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
- (2015) Michael S. Rooney et al. CELL
- Biomarker: Predictive or Prognostic?
- (2015) Karla V. Ballman JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
- (2015) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)
- (2015) Donavan T. Cheng et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
- (2015) S. P. Patel et al. MOLECULAR CANCER THERAPEUTICS
- Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
- (2015) Dongjun Peng et al. NATURE
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoantigens in cancer immunotherapy
- (2015) T. N. Schumacher et al. SCIENCE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice
- (2015) Luís Felipe Campesato et al. Oncotarget
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- TCR repertoires of intratumoral T-cell subsets
- (2013) Carsten Linnemann et al. IMMUNOLOGICAL REVIEWS
- Signatures of mutational processes in human cancer
- (2013) Ludmil B. Alexandrov et al. NATURE
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
- (2013) Garrett M Frampton et al. NATURE BIOTECHNOLOGY
- Evidence for APOBEC3B mutagenesis in multiple human cancers
- (2013) Michael B Burns et al. NATURE GENETICS
- The Peptide-Receptive Transition State of MHC Class I Molecules: Insight from Structure and Molecular Dynamics
- (2012) M. G. Mage et al. JOURNAL OF IMMUNOLOGY
- Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
- (2012) Hirokazu Matsushita et al. NATURE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now